Skip to content
    PBYI
    Earnings call· Jun 2026(Q2 FY26)

    PUMA BIOTECHNOLOGY Q2 FY26 earnings call PBYI

    Aug 6, 2026 Source

    Executive summary

    Puma Biotechnology Q2 FY26 — Strong NERLYNX Sales and Positive Net Income Guidance

    Puma Biotechnology delivered a strong second quarter, driven by robust NERLYNX sales and increased demand, leading to an upward revision in full-year revenue and net income guidance. The company also achieved a significant financial milestone by becoming debt-free. While new prescriptions saw a slight decline, the focus remains on commercial execution and advancing the alisertib clinical pipeline, with plans to initiate Phase III trials in the future.

    Highlights

    5
    • Product revenue net increased to $53.6 million in Q2 FY26, up from $42 million in Q1 FY26 and $49.2 million in Q2 FY25.

    • NERLYNX ex-factory bottle sales were 2,929, representing an approximate 26% increase quarter-over-quarter and 12% increase year-over-year.

    • U.S. demand for NERLYNX was 2,986 bottles, an 8% increase quarter-over-quarter and 11% increase year-over-year.

    • The company is now debt-free after making the final $11.1 million principal loan payment related to its obligation with Athyrium.

    • Full-year 2026 net NERLYNX product revenue guidance was raised to $205 million to $209 million, up from prior guidance of $202 million to $206 million.

    Concerns

    3
    • New prescriptions for NERLYNX were down approximately 6% compared to Q1 FY26.

    • Full-year 2026 royalty revenue guidance was slightly lowered to $19 million to $22 million, from prior guidance of $20 million to $23 million, due to potential generic erosion in China.

    • The gross-to-net adjustment in Q2 FY26 was higher at 27.9% compared to 27% in Q1 FY26, driven by higher Medicaid share.

    Guidance & targets

    10
    CategoryTargetConfidence
    Full-year 2026 net NERLYNX product revenue
    $205 million to $209 million
    high materiality
    High
    Full-year 2026 gross to net adjustment
    26.5% and 27.5%
    medium materiality
    Medium
    Full-year 2026 royalty revenue
    $19 million to $22 million
    medium materiality
    Medium
    Full-year 2026 net income
    $17 million to $20 million
    high materiality
    High
    Q3 2026 NERLYNX product revenue net
    $54 million to $56 million
    medium materiality
    Medium
    Q3 2026 royalty revenues
    $2 million to $3 million
    medium materiality
    Medium
    Q3 2026 gross to net adjustment
    approximately 26% to 27%
    medium materiality
    Medium
    Q3 2026 net income
    $2 million and $2.5 million
    medium materiality
    Medium
    Full-year 2026 SG&A expenses
    increase by 1% to 2%
    medium materiality
    Medium
    Full-year 2026 R&D expenses
    increase by 34% to 37%
    medium materiality
    Medium

    Segment performance

    2
    SegmentRevenueYoYQoQMargin
    NERLYNX Product Revenue Net
    Strong growth in product revenue and bottle sales, driven by increased demand in the specialty distributor channel. Inventory decreased by $1 million.
    Product supply revenue to international partners: $23,000U.S. net sales of NERLYNX: $53.6 millionInventory decrease: $1 millionEx-factory bottle sales: 2,929Ex-factory bottle sales growth QoQ: 26%Ex-factory bottle sales growth YoY: 12%Inventory decrease (bottles): 57U.S. demand: 2,986 bottlesU.S. demand growth QoQ: 8%U.S. demand growth YoY: 11%Specialty pharmacy channel share: 61%Specialty distributor channel share: 39%Specialty distributor channel demand growth QoQ: 12%Specialty distributor channel demand growth YoY: 32%Call activity increase YoY: 18%Call activity increase QoQ: 2%Total prescriptions (TRx) increase QoQ: 7%Total prescriptions (TRx) increase YoY: 3%Enrollments growth QoQ: 1%Enrollments growth YoY: 12%Commercial new patient starts decline QoQ: 6%Commercial new patient starts growth YoY: 8%Patients starting NERLYNX at reduced dose: 73%
    $53.6 million8.9% increase27.6% increase
    Royalty Revenue
    Royalty revenue remained relatively stable quarter-over-quarter but declined year-over-year.
    $2.9 million-9.4% decrease3.6% increase

    Operational metrics

    16
    Net income (GAAP)
    $8.2 millionvs. net loss of $3.8 million in Q1 2026
    Q2 2026
    Diluted EPS (GAAP)
    $0.16vs. net loss of $0.07 per share in Q1 2026
    Q2 2026
    Net income (non-GAAP)
    $10.1 million
    Q2 2026
    Diluted EPS (non-GAAP)
    $0.19
    Q2 2026
    Gross revenue from NERLYNX sales
    $74.3 millionvs. $57.5 million in Q1 2026
    Q2 2026
    Gross to net adjustment
    27.9%vs. 27% in Q1 2026
    Q2 2026
    Cost of sales
    $12.5 millionvs. $10.4 million in Q1 2026
    Q2 2026
    SG&A expenses
    $17.5 millionvs. $18.4 million in Q1 2026
    Q2 2026
    R&D expenses
    $18.9 millionvs. $19.8 million in Q1 2026
    Q2 2026

    transcription_note: $0.8 million stated in transcript, but $0.7 million is likely correct based on Q1 comparison and typical rounding.

    Cash burn
    $9.7 millionvs. $4 million in Q1 2026
    Q2 2026
    Principal loan payment
    $11.1 millionfinal quarterly payment
    Q2 2026

    Company is now debt-free.

    Cash, cash equivalents and marketable securities
    $93.9 millionvs. $97.5 million at year-end 2025
    as of June 30, 2026
    Accounts receivable balance
    $34.1 million
    as of June 30, 2026
    Days sales outstanding (DSO)
    44 days
    as of June 30, 2026

    Accounts receivable terms range between 10 and 68 days.

    Distribution network inventory
    3 weeks
    as of June 30, 2026
    Manufacturing product cost as % of COGS
    mid- to high single-digit percentage
    FY26

    As a point of reference, our manufacturing product cost accounts for a mid- to high single-digit percentage of our total cost of goods sold.

    Industry KPIs

    7
    MetricValueDetails
    Launch access metrics73%%
    Pipeline read out calendarALISCA-Lung1 interim data update in Q4 2026; ALISCA-Lung2 initial data in 2027
    Product franchise net sales$53.6 millionUSD
    Regulatory approvals filingsNERLYNX launched in Thailand
    Prescription volume new starts2,929 bottles sold (ex-factory)bottles
    Clinical trial efficacy safety dataPreliminary indication of potentially better activity
    Collaboration milestone royalty revenue$2.9 millionUSD

    Product announcements

    1
    ProductTypeDetails
    NERLYNXlaunch

    Deals & partnerships

    1
    International partnersSublicense agreement covering China for NERLYNX

    The threshold for royalty rate reduction could be reached in late 2026 or 2027.

    Risks & headwinds

    3
    Generic competition in China for NERLYNXLate 2026 or 2027

    Potential royalty rate reduction

    Mitigation: Not explicitly stated, but implies monitoring and managing expectations.

    Higher gross to net adjustmentQ2 2026

    27.9% in Q2 2026 vs 27% in Q1 2026

    Mitigation: Driven by higher Medicaid share, no specific mitigation stated.

    New prescriptions declineQ2 2026

    Down approximately 6% compared to Q1 2026

    Mitigation: Continued messaging, adoption of dose escalation, and patient education resources.

    What to watch in Q3 FY26

    5

    Alisertib ALISCA-Breast1 enrollment

    Q3 FY26
    CurrentProtocol amended, enrollment paused in some groups.
    TargetBegin enrollment under amended protocol.

    Why it matters

    Indicates progress in the clinical development of alisertib, a key pipeline asset.

    That amendment to the protocol has been submitted to the FDA and the EU authorities and is being submitted to the IRBs as well. We are hoping to begin enrollment under that amended protocol in Q3.

    Q&A highlights

    2

    What is the R&D spend trajectory beyond Q3 FY26 into FY27, and can Puma fund Phase III trials for both alisertib indications?

    Alan Auerbach confirmed that based on current projections, Puma can fund Phase III trials for both alisertib in ER-positive breast cancer and small cell lung cancer, likely staggering them. He emphasized that being debt-free and cash flow positive enables this investment, and the company is committed to maintaining positive net income.

    So in terms of the R&D in '27, '28, '29, we've gotten this question from investors before, which is, let's say you want to do the Phase III trials of both alisertib in ER-positive breast cancer and in small cell lung cancer. Can you do that? And the answer to that is according to our current projections, yes.

    asked by Marc Frahm · answered by Alan Auerbach

    2 min read6 chapters

    Detailed Narrative

    01

    NERLYNX Commercial Performance

    Puma reported strong Q2 FY26 NERLYNX product revenue net of $53.6 million, an increase from $42 million in Q1 FY26 and $49.2 million in Q2 FY25. Ex-factory bottle sales reached 2,929, representing a 26% quarter-over-quarter and 12% year-over-year increase. U.S. demand grew 8% quarter-over-quarter and 11% year-over-year to 2,986 bottles, primarily driven by the specialty distributor channel which saw 32% year-over-year growth. The company estimates inventory decreased by $1 million in Q2 FY26.

    02

    Alisertib Clinical Development Progress

    The company is advancing two Phase II trials for its investigational drug alisertib: ALISCA-Breast1 (HER2-negative ER-positive breast cancer) and ALISCA-Lung1 (small cell lung cancer). The ALISCA-Breast1 protocol was amended to focus enrollment on 40mg and 50mg dose groups based on interim data suggesting potentially better activity in patients with specific biomarkers. For ALISCA-Lung1, the dose was further increased to 70mg BID, with 92 patients currently enrolled. Interim data from ALISCA-Lung1, including longer-term follow-up, is expected in Q4 FY26.

    03

    Future Alisertib Trials and Funding Outlook

    Puma plans to initiate a second alisertib trial in small cell lung cancer, ALISCA-Lung2, in Q3 FY26, which will combine alisertib with paclitaxel. Initial data for ALISCA-Lung2 is anticipated in 2027. Management expressed confidence in the company's ability to fund potential Phase III trials for both alisertib indications in 2027, noting that they may stagger the trials if necessary to maintain positive net income, leveraging their newly debt-free status.

    04

    Financial Strength and Capital Allocation

    Puma achieved a significant financial milestone by becoming debt-free in Q2 FY26, having made its final $11.1 million principal loan payment to Athyrium. The company reported $93.9 million in cash, cash equivalents, and marketable securities as of June 30, 2026. Management reiterated its commitment to maintaining positive net income and is actively evaluating in-licensing or acquiring commercial or development-stage drugs to diversify its portfolio and leverage existing infrastructure.

    05

    Marketing and Sales Strategy

    Marketing initiatives are focused on increasing awareness of NERLYNX's dual indication in HER2-positive breast cancer (early and metastatic settings) and addressing unmet needs. The sales team prioritizes patients at higher risk of recurrence, clinical education, and patient resources to support persistence and compliance. Dose escalation remains an important commercial priority, with 73% of patients starting NERLYNX at a reduced dose.

    06

    Royalty Revenue and Generic Risk

    Full-year royalty revenue guidance was slightly lowered due to the potential for generic versions of NERLYNX reaching a specific market share threshold in China in late 2026 or 2027. This threshold, if met, would trigger a reduction in the royalty rate payable to Puma under its sublicense agreement covering China.

    AI-generated summary of the company’s earnings call. Not investment advice.